EMA Authorised: NovoSeven (eptacog alfa (activated)) — Novo Nordisk A/S

View source ↗

Summary

The EMA authorised NovoSeven (eptacog alfa activated) from Novo Nordisk A/S for multiple indications including Hemophilia A/B, Factor VII deficiency, and thromb…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Factor Vii Deficiency
• Hemophilia
• Thrombasthenia

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Status: Authorised. Therapeutic area: Hemophilia B;Thrombasthenia;Factor VII Deficiency;Hemophilia A. MAH: Novo Nordisk A/S. Decision date: 23/02/2023